Medicare AdvantagePrior AuthMedium impact
Onureg™ (azacitidine) (Revised)
Humana·Hematology, Oncology·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has established new prior authorization requirements for Onureg (azacitidine) tablets for acute myeloid leukemia treatment, effective January 1, 2026. The policy requires specific criteria including complete remission status and inability to complete intensive curative therapy.
Action Required
By January 1, 2026: Billing team must obtain prior authorization from Humana for all Onureg (azacitidine) prescriptions for Medicare Advantage patients with acute myeloid leukemia. Verify patient meets all 5 criteria including complete remission status and inability to complete intensive therapy. Visit www.humana.com/PAL for medical and procedural coding requirements. Claims will be denied without proper prior authorization.